In prostate cancer, OXER1 has a survival promoting effect40; siRNA for OXER1 significantly reduces the viability of prostate cancer cells and lately the use of agents that suppress 5-LOX activity or LOX-mediated signaling pathways have been proposed as new therapeutic tools in cancer27. The gene discussed is LOX; the disease is prostate carcinoma.